July 17, 2014
1 min read

Dorzolamide/timolol fixed combination effective for normal-tension glaucoma

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Researchers have found dorzolamide/timolol fixed combination to be an effective IOP-lowering agent for patients with normal-tension glaucoma.

A prospective, open-label, multicenter study included 37 patients with treatment-naïve, normal-tension glaucoma who received dorzolamide/timolol fixed combination therapy for 12 weeks to reduce IOP. For each visit, the researchers measured patients’ IOP at 9 a.m. prior to the administration of dorzolamide/timolol fixed combination therapy; IOP was then measured again at 11 a.m. and 5 p.m. IOP was also measured at 1 p.m. and 3 p.m. at the 12-week follow-up.

At the time of peak drug effect (11 a.m.), the researchers noted a significant reduction in IOP from baseline at the 12-week follow-up (11.9 mm Hg vs. 15.6 mm Hg; P < .0001). A significant IOP reduction was also observed at trough drug effect at 9 a.m. and 8 hours following drug administration at 5 p.m. (P < .0001).

The most commonly reported adverse event was eye irritation (59.5%) and ocular hyperemia (16.2%). However, the eye irritations appeared to be mild in intensity, according to the researchers.

Disclosure: Park and Kim have received honoraria from Alcon Laboratories, Allergan, Merck and Pfizer, as well as investigator fees from MSD Korea Ltd. Merck designed and sponsored the study.